Ikra Tablets 50 mg & 100 mg | Product Information

Ikra Tablets 50 mg & 100 mg: Product Overview

Ikra Tablets 50 mg and 100 mg are oral tablet strengths associated with venetoclax, a prescription medicine used in the treatment of certain blood cancers. The exact composition, manufacturer and regulatory status should be verified against the product documentation before purchase or distribution.

Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical product information to support healthcare professionals, distributors and international pharmaceutical buyers seeking reliable details about medicines and their availability.

What Are Ikra Tablets Used For?

Venetoclax belongs to a class of medicines known as BCL-2 inhibitors. It works by blocking the BCL-2 protein, which can help certain cancer cells survive. This action can promote programmed cell death in susceptible cancer cells.

Depending on the approved indication, treatment protocol and combination regimen, venetoclax may be prescribed for certain patients with:

Chronic lymphocytic leukaemia (CLL): A type of blood cancer affecting lymphocytes.

Acute myeloid leukaemia (AML): A cancer of the blood and bone marrow, treated with venetoclax in specific combination regimens.

Other approved indications: Eligibility depends on the applicable national prescribing information.

Treatment must be supervised by a qualified haematologist or oncologist.

Potential Benefits of Ikra Tablets

When prescribed for an appropriate indication, venetoclax may offer the following therapeutic benefits:

Targeted mechanism of action: Inhibits the BCL-2 protein involved in cancer cell survival.

Oral administration: Available as tablets for use according to a prescribed treatment plan.

Combination treatment options: May be used alongside other anticancer medicines for specific conditions.

Clinically guided treatment: Allows specialists to select an appropriate regimen based on the patient's diagnosis and clinical circumstances.

Individual outcomes vary. These benefits do not guarantee a particular treatment response or outcome.

Ikra Tablets 50 mg & 100 mg: Possible Side Effects

Venetoclax may cause side effects that require medical supervision. Possible adverse effects include:

Nausea, diarrhoea or vomiting

Fatigue and weakness

Anaemia or low red blood cell counts

Low white blood cell counts, increasing infection risk

Low platelet counts, which may increase bleeding risk

Tumour lysis syndrome, a potentially life-threatening complication caused by the rapid breakdown of cancer cells

Seek urgent medical attention for fever, unusual bleeding, severe weakness, reduced urine output or other concerning symptoms. Your healthcare professional may recommend blood tests, preventive measures and dose adjustments.

Safety Precautions and Administration

Take Ikra only if prescribed by an authorised healthcare professional. The dose and schedule depend on the diagnosis, treatment combination, other medicines and individual risk factors.

Venetoclax treatment can require gradual dose escalation, laboratory monitoring and measures to reduce tumour lysis syndrome risk. Inform your doctor about kidney or liver problems, infections, pregnancy, breastfeeding and all prescription medicines, supplements and herbal products.

Drug interactions can be significant. Do not start, stop or change treatment without medical advice.

Frequently Asked Questions About Ikra Tablets

1. What is the active ingredient in Ikra Tablets?

Ikra 50 mg and 100 mg products are associated with venetoclax in available medicine listings. Confirm the composition on the specific product label before use or distribution.

2. What is the difference between Ikra 50 mg and 100 mg?

The stated strength differs. Neither strength should be substituted for the other without instructions from the treating specialist.

3. Can Ikra Tablets be taken without a prescription?

No. Venetoclax is a prescription anticancer medicine requiring specialist supervision.

4. What are the common side effects?

Possible effects include nausea, diarrhoea, fatigue, anaemia and low blood cell counts. Serious complications can also occur.

5. How can international buyers enquire about Ikra Tablets?

Healthcare distributors and pharmaceutical importers can contact Cordium Pharmaceuticals Pvt Ltd to request verified product specifications, packaging details, applicable regulatory documentation and export availability.

Contact Cordium Pharmaceuticals Pvt Ltd

For product enquiries concerning Ikra Tablets 50 mg and 100 mg, contact Cordium Pharmaceuticals Pvt Ltd for further information. International supply is subject to product availability, applicable registrations, import requirements and local pharmaceutical regulations.

Medical disclaimer: This page is for general product information and is not a substitute for approved prescribing information or professional medical advice. Always verify the product composition and consult a qualified healthcare professional before treatment.